title: Terazosin therapy for patients with female lower urinary tract symptoms: a randomized, double-blind, placebo controlled trial.
abstract: OBJECTIVE
  We determined the clinical efficacy and safety of terazosin in the treatment of patients with female lower urinary tract symptoms.
  
  
  METHODS
  A total of 100 females 20 to 70 years old who met the inclusion criteria of total International Prostate Symptom Score 8 or greater, symptom duration 1 or more months, and did not meet any exclusion criteria were entered into the study. Subjects were randomized to receive terazosin or placebo in titrated dose from 1 mg od, 1 mg twice daily to 2 mg twice daily during 14 weeks. Successful treatment outcomes use primary end point of International Prostate Symptom Score quality of life 2 or less and secondary end point of total International Prostate Symptom Score 7 or less. Other outcome measures included International Prostate Symptom Score individual item scores, King's Health Questionnaire quality of life domains, objective assessment parameters of 24-hour frequency volume chart, maximum flow rate and post-void residual urine.
  
  
  RESULTS
  Using a primary end point, 32 of 40 (80%) evaluable terazosin subjects responded in contrast to 22 of 40 (55%) evaluable placebo subjects (p <0.02). The secondary end point revealed a successful outcome in 85% of terazosin subjects vs 55% in placebo (p <0.01). Of the 7 International Prostate Symptom Score individual item scores, only item scores of frequency and straining showed statistically significant reductions with terazosin (p <0.01). All King's Health Questionnaire quality of life domains except domain of severity measures showed statistically significant improvement with terazosin (p <0.05). There were no differences between treatment groups in all objective assessment parameters. Of all evaluable subjects 23 of 40 (58%) on placebo experienced adverse events vs 16 of 40 (40%) on terazosin (p >0.05).
  
  
  CONCLUSIONS
  Terazosin proved to be more effective and safe than placebo in patients with female lower urinary tract symptoms.
authors.affiliation: School of Pharmaceutical Sciences, University of Science Malaysia, Penang, Malaysia.
authors.forename: Bee Yean
authors.initials: BY
authors.lastname: Low
authors.forename: Men Long
authors.initials: ML
authors.lastname: Liong
authors.forename: Kah Hay
authors.initials: KH
authors.lastname: Yuen
authors.forename: Christopher
authors.initials: C
authors.lastname: Chee
authors.forename: Wing Seng
authors.initials: WS
authors.lastname: Leong
authors.forename: Wooi Loong
authors.initials: WL
authors.lastname: Chong
authors.forename: Nurzalina Abdul Karim
authors.initials: NA
authors.lastname: Khan
authors.forename: Phaik Yeong
authors.initials: PY
authors.lastname: Cheah
authors.forename: Ker Keong
authors.initials: KK
authors.lastname: Liong
mesh_terms: D000317:Adrenergic alpha-Antagonists / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008875:Middle Aged; D011224:Prazosin / Q000031:analogs & derivatives* / Q000627:therapeutic use; D014555:Urination Disorders / Q000188:drug therapy*
chemical_list: D000317:Adrenergic alpha-Antagonists; C041226:Terazosin; D011224:Prazosin